TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10446825
Drug: IL-1beta (6.25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-1beta (6.25, 12.5, 50, or 200 pg/mL for 20 mins)
Study: 10446825
Drug: TNF-alpha (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNF-alpha (1.25 pg/mL) plus IL-1beta (6.25 pg/mL)
Study: 10446825
Drug: Ceramidase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceramidase inhibitor N-oleoyl ethanolamine (1 microM) or NO synthase inhibitor N(G)-monomethyl-L-arginine (10 microM)
Study: 313765
Drug: Group 2
Normalized name: Chlamydophila psittaci biogroup 2 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2 (n = 120) received a bolus of hypertonic glucose, insulin, and potassium in the pump perfusate before aortic cross‐clamping.
Study: 313765
Drug: Group 3
Normalized name: Chlamydophila psittaci biogroup 3 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 3 (n = 114) had the aortic root continuously infused with glucose, insulin, and potassium solution at 4 degrees C during aortic cross‐clamping.
Study: 313765
Drug: Control Group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Group 1 (n = 157) received no additional glucose, insulin, and potassium solutions.
Study: 29386049
Drug: Intrathecal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal administration of autologous bone marrow mononuclear cells and standard neurorehabilitation
Study: 24574125
Drug: Budesonide (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (0.25 mg)
Study: 22356215
Drug: Controlled-release (CR)
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Controlled-release (CR) orally disintegrating tablets (ODT) and CR capsules (50 mg)
Study: 22356215
Drug: Immediate-release (IR)
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release (IR) syrup (reference)
Study: 21044101
Drug: n-3 supplement
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 supplement (TheraTears Nutrition®)
Study: 17568957
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group using handheld computers for daily surveys
Study: 15930540
Drug: Low-dose shock
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose shock wave therapy without anesthetic
Study: 15930540
Drug: Crossover patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crossover patients receiving active treatment after placebo
Study: 11845223
Drug: Prednisolone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (30 mg/day for 6 days)
Study: 10417465
Drug: Group 1:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1: Ophthalmic drape A
Study: 10417465
Drug: Group 2:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2: Ophthalmic drape B
Study: 10417465
Drug: Group 3:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 3: Ophthalmic drape C
Study: 2205624
Drug: Continuous combined
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous combined estrogen/progestogen therapy (2 mg estradiol + 1 mg norethisterone acetate + 500 mg calcium daily)
Study: 2205624
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + 500 mg calcium daily
Study: 6992626
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg oral terbutaline
Study: 6992626
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg terbutaline t.i.d. for a week
Study: 24386900
Drug: Twice-weekly, physiotherapist-led
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly, physiotherapist-led exercise classes
Study: 21593280
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg ilaprazole once daily for 7 days
Study: 19942720
Drug: Intramuscular electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular electrical stimulation at latent MTrPs
Study: 9797593
Drug: EMG biofeedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMG biofeedback training and conventional medical treatment (BFT)
Study: 9797593
Drug: Conventional medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional medical treatment alone (Control)
Study: 2694330
Drug: Pirenzepine treatment
Normalized name: pirenzepine
DrugBank: Pirenzepine (DB00670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine treatment for 4 weeks
Study: 31968301
Drug: Within-treatment frequency
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Within-treatment frequency of use
Study: 31968301
Drug: Within-treatment abstinence
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Within-treatment abstinence
Study: 30575054
Drug: No antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotic (Group A)
Study: 30575054
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) antibiotic for 1 day (Group B)
Study: 30575054
Drug: 1 day
Normalized name: ZonaCort 11 Day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 day IV plus 7 days oral antibiotic (Group C)
Study: 28421639
Drug: cilostazol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: cilostazol (50 mg twice a day)
Study: 26537207
Drug: Secondary sentinel
Normalized name: Sentinel Spectrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secondary sentinel lymph node (SSLN) tracing technique with Methylthioninium chloride injection in group A (138 patients)
Study: 23789213
Drug: Dingqi analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dingqi analgesic patch
Study: 23789213
Drug: Sham patch
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham patch (Control)
Study: 11097156
Drug: Antisense oligodeoxynucleotides
Normalized name: Exon 53 specific antisense morpholino oligonucleotide
DrugBank: Viltolarsen (DB15005)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Antisense oligodeoxynucleotides at 200, 400, and 800 micromol/L
Study: 11097156
Drug: Sense oligodeoxynucleotides
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sense oligodeoxynucleotides at 100, 200, 400, and 800 micromol/L
Study: 1352049
Drug: Concurrent mental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent mental state abnormalities
Study: 26678391
Drug: Inert control
Normalized name: inert ingredients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inert control pill
Study: 23240877
Drug: Nd:YAG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nd:YAG laser irradiation at 1W (group G)
Study: 21501001
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive containing 35 μg ethinyl estradiol and 2 mg cyproterone acetate
Study: 19673711
Drug: Heparin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin plus GPI
Study: 14675269
Drug: Omeprazole treatment
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole treatment for 4 weeks
Study: 3170995
Drug: Immunotherapy (IT)
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy (IT) with birch extract
Study: 27697671
Drug: Supportive-therapy control
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive-therapy control
Study: 16019088
Drug: GTN protocol
Normalized name: GTN
Approvals — FDA: no, EMA: no, PMDA: no
Description: GTN protocol (70 degree tilt, 35 min, CSM at 5 min, 400 microg of glyceryl trinitrate spray administered sublingually at 20 min)
Study: 16019088
Drug: Drug-free protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-free protocol (70 degree tilt, 45 min, CSM at 5 and 45 min)
Study: 10566612
Drug: Single agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single agents (platinum analog or vinorelbine)
Study: 8807070
Drug: Trovafloxacin 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trovafloxacin 50 mg
Study: 9758289
Drug: Trovafloxacin 100
Normalized name: trovafloxacin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trovafloxacin 100 mg
Study: 8522468
Drug: Trovafloxacin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trovafloxacin (all doses)
Study: 1391670
Drug: Piracetam (4,800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piracetam (4,800 mg/d for three months)
Study: 20493532
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation with imipramine treatment
Study: 20493532
Drug: Placebo supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo supplementation with imipramine treatment
Study: 20493532
Drug: Imipramine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine treatment (with or without zinc supplementation)
Study: 20493532
Drug: Imipramine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine treatment (with zinc supplementation)
Study: 12236844
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg moxonidine alone
Study: 12236844
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg quinidine sulphate with 0.2 mg moxonidine
Study: 10416909
Drug: Passing a
Normalized name: factor VIII inhibitor bypassing activity
DrugBank: Anti-inhibitor coagulant complex (DB13151)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passing a daily screen of weaning parameters
Study: 9419612
Drug: 40 ml
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 ml iohexol
Study: 9419612
Drug: 40 ml
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 ml ioxaglate
Study: 29471381
Drug: Prior failure
Normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior failure of antibiotic therapy
Study: 26983548
Drug: Memantine (5-15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine (5-15 mg/day)
Study: 25248944
Drug: Nurse-led titration
Normalized name: PAD,NURSING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-led titration (NLT) clinic
Study: 18036357
Drug: Modified glucose-insulin-potassium
Normalized name: glucose / potassium chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified glucose-insulin-potassium (GIK) regimen (insulin 2.5 U/hour, dextrose and potassium titrated to prevent hyperglycemia)
Study: 18036357
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline solution and potassium (controls)
Study: 18036357
Drug: Modified glucose-insulin-potassium
Normalized name: glucose / potassium chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified glucose-insulin-potassium (GIK) regimen
Study: 11898063
Drug: 10 mg/d
Normalized name: Arixtra 10 mg/dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/d of alendronate for 10 weeks (A)
Study: 11898063
Drug: 20 mg/d
Normalized name: Valtoco, 20 mg/dose nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/d of alendronate for 5 weeks (B)
Study: 1322780
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (C)
Study: 7485937
Drug: Midwife-Administered Intermittent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midwife-Administered Intermittent Bolus (IB) Epidural Analgesia
Study: 2097716
Drug: Gentamicin or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin or netilmicin given by once daily or thrice daily injections
Study: 2097716
Drug: Conventional monitoring
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional monitoring of aminoglycoside treatment
Study: 23452521
Drug: 10-second methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10-second methylprednisolone injection
Study: 23452521
Drug: 30-second methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30-second methylprednisolone injection
Study: 19474132
Drug: Skim milk
Normalized name: skim milk
DrugBank: Skim milk (DB15546)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skim milk (600 mL; 25 g protein, 36 g lactose, <1 g fat; 1062 kJ)
Study: 19474132
Drug: Fruit drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fruit drink (600 mL; <1 g protein, 63 g sugar, <1 g fat; approximately 1062 kJ)
Study: 28560658
Drug: Adefovir dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adefovir dipivoxil 10 mg
Study: 14975536
Drug: Troponin T
Normalized name: Troponin T
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troponin T elevation (>0.1 microg/l)
Study: 14975536
Drug: Troponin T
Normalized name: Troponin T
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troponin T results (>0.1 vs. < or =0.1 microg/l)
Study: 7950335
Drug: 0.5g imipenem
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5g imipenem infusion
Study: 7950335
Drug: 1g imipenem
Normalized name: Imipenem
DrugBank: Imipenem (DB01598)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1g imipenem infusion
Study: 31813637
Drug: Ixekizumab Q4W
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixekizumab Q4W (80 mg every 4 weeks)
Study: 31813637
Drug: Ixekizumab Q2W
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixekizumab Q2W (80 mg every 2 weeks)
Study: 28114846
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg progesterone pessaries, twice daily, started in the luteal phase and continued after a positive pregnancy test till 28 weeks of gestation
Study: 28114846
Drug: Placebo, twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, twice daily, started in the luteal phase and continued after a positive pregnancy test till 28 weeks of gestation
Study: 28114846
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg progesterone pessaries
Study: 26643116
Drug: 7 days
Normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 days high dose primaquine
Study: 26643116
Drug: 14 days
Normalized name: ponesimod
DrugBank: Ponesimod (DB12016)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 14 days high dose primaquine
Study: 26643116
Drug: Weekly primaquine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly primaquine doses for 8 weeks (for G6PD deficient patients)
Study: 20736505
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg once daily for at least 2 weeks
Study: 20736505
Drug: Rabeprazole 20
Normalized name: RABEprazole 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 20 mg once daily for at least 2 weeks
Study: 20736505
Drug: Post-treatment comparison
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment comparison between omeprazole and rabeprazole groups
Study: 15886723
Drug: 20 mg/day
Normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/day racemic fluoxetine
Study: 15886723
Drug: 80 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg/day R-fluoxetine
Study: 15886723
Drug: 120 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg/day R-fluoxetine
Study: 12818939
Drug: Rofecoxib (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib (1 mg/kg)
Study: 10912700
Drug: Gentamicin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin therapy administered transtympanically
Study: 6366725
Drug: T4 therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: T4 therapy
Study: 31574237
Drug: Nonoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative treatment in patients aged ≥50 years
Study: 30212948
Drug: Rational Emotive
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rational Emotive Behavior Therapy (REBT) intervention for 12 weeks and a follow-up program for 2 weeks
Study: 27465076
Drug: Intragastric balloon
Normalized name: CATHETER,BALLOON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intragastric balloon (IGB) therapy
Study: 22038680
Drug: Rectal balloon
Normalized name: CATHETER,BALLOON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal balloon training (RBT) with pelvic floor muscle training (PFMT)
Study: 19852282
Drug: Shengjing Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shengjing Capsule at a dose of 1.6 g tid for 12 weeks
Study: 19852282
Drug: Vit E
Normalized name: tocopherol (vit E)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vit E at 50 mg tid for 12 weeks
Study: 10519449
Drug: Gasec-40 Gastrocaps
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gasec-40 Gastrocaps (40 mg daily for 5 days)
Study: 10519449
Drug: Antra 40
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antra 40 (40 mg daily for 5 days)
Study: 7500507
Drug: Step II
Normalized name: STEP 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Step II Diet and lovastatin (40 mg daily) plus colestipol (30 g daily)
Study: 1789528
Drug: Simvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (10 or 20 mg once a day, with a doubling of the dosage at week 6 if LDL-cholesterol level remained above 1.40 g/l)
Study: 1789528
Drug: Bezafibrate (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bezafibrate (600 mg 3 times a day, with a doubling of the dosage at week 6 if LDL-cholesterol level remained above 1.40 g/l)
Study: 30715997
Drug: Buparlisib 100
Normalized name: Buparlisib
DrugBank: Buparlisib (DB11666)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buparlisib 100 mg once daily on a continuous 28-day schedule (cohort 1)
Study: 30715997
Drug: Buparlisib 100
Normalized name: Buparlisib
DrugBank: Buparlisib (DB11666)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buparlisib 100 mg once daily on a continuous 28-day schedule (cohort 2)
Study: 30715997
Drug: Buparlisib 100
Normalized name: Buparlisib
DrugBank: Buparlisib (DB11666)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buparlisib 100 mg once daily on a continuous 28-day schedule
Study: 29488430
Drug: Optimized dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized dose of PPI (Control)
Study: 19602758
Drug: Oral drotaverine
Normalized name: drotaverin
DrugBank: Drotaverine (DB06751)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral drotaverine (80 mg) plus mefenamic acid (250 mg)
Study: 19602758
Drug: Intravenous sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sedation with diazepam
Study: 19602758
Drug: Oral drotaverine
Normalized name: drotaverin
DrugBank: Drotaverine (DB06751)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral drotaverine plus mefenamic acid
Study: 17785361
Drug: Supraphysiological GH
Normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supraphysiological GH therapy
Study: 15189751
Drug: TLA 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: TLA 0.5% solution once daily
Study: 15189751
Drug: TIM 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIM 0.5% ophthalmic solution twice daily
Study: 7905369
Drug: Propafenone plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone plus quinidine sulfate (60 mg orally every 8 hours)
Study: 2577015
Drug: Nifedipine sublingual
Normalized name: nifedipine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine sublingual 10-20 mg alone (group I, n = 19)
Study: 2577015
Drug: Nifedipine sublingual
Normalized name: nifedipine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine sublingual 10-20 mg associated with furosemide and clonidine (group II, n = 29)
Study: 186089
Drug: Thymoxamine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymoxamine (150 mg i.v.)
Study: 31218354
Drug: Ticagrelor 60
Normalized name: ticagrelor 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor 60 mg b.i.d.
Study: 23085743
Drug: Daptomycin 4
Normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daptomycin 4 mg/kg once daily for 7-14 days
Study: 23085743
Drug: Vancomycin 1
Normalized name: vancomycin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin 1 g twice daily for 7-14 days
Study: 18470565
Drug: 0.2 percent
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 percent glyceryl trinitrate suppository (n = 21)
Study: 16482475
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of WBV and squat (S+V)
Study: 3313041
Drug: Gemfibrozil (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil (600 mg twice daily)
Study: 8103616
Drug: 300 mg/daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/daily ranitidine
Study: 8103616
Drug: 40 mg/daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/daily famotidine
Study: 8103616
Drug: 300 mg/daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/daily nizatidine
Study: 8103616
Drug: 40 mg/daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/daily omeprazole
Study: 26151620
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (32 IU)
Study: 14994771
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg moxifloxacin (oral)
Study: 9488244
Drug: CS-866 10
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS-866 10 mg
Study: 9488244
Drug: CS-866 20
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS-866 20 mg
Study: 9488244
Drug: CS-866 80
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS-866 80 mg
Study: 9488244
Drug: CS-866 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS-866 (all doses above 5 mg)
Study: 9488244
Drug: CS-866 (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS-866 (2.5 to 10 mg and 5 to 20 mg)